Forgot your password?
The decision is expected to benefit up to 14,000 patients living with the autoimmune disease
The candidate has been developed up to mid-stage in non-dermatological indications
Amtagvi was authorised for use under the US regulator’s accelerated approval pathway
The long-term skin condition affects approximately 2% of the Scottish population
The new company was co-founded by Medicxi and several dermatology and scientific experts
The project builds on the ongoing non-melanoma skin cancer research agreement between the partners
The inflammatory skin disease affects approximately 1% of the population in most studied countries
The DELTA FORCE study has been comparing twice-daily delgocitinib cream with once-daily alitretinoin capsules
More than 125 million people worldwide are estimated to be living with plaque psoriasis
The inflammatory skin disease affects more than 26 million people in the US